regardless of encouraging clinical data, copyright's Vyndamax, a therapy for hereditary transthyretin-mediated amyloidosis (hATTR), is facing substantial difficulty from PBMs. The insurers are frequently erecting obstacles to access, such as steep price requirements and PA that restrict patient access. Market believe that these reimbursement hurdle